OXNARD, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug
delivery technology and pharmaceutical cannabinoid molecule development company, announced today that the CURE and the CannaKids
partnership has entered into a strategic research collaboration with Technion Research and Development Foundation Ltd., wholly
owned subsidiary of the Technion-Israel Institute of Technology, in order to research how different cannabinoid compounds within
cannabis strains can be used to treat various subtypes of cancer.
Researchers from CURE’s Pharmaceutical Cannabinoid Division and Technion’s Laboratory of Cancer Biology and Cannabinoid Research
will work together to research and identify how varying cannabinoid compounds within cannabis strains can affect various cancer
subtypes. The results of the research will be used to predict how to match a cancer subtype with an effective cannabis extract in
order to optimize treatment efficacy.
“When I first traveled to Israel to meet Professor Meiri and his team at Technion in search for more help for my own daughter’s
brain tumor, I was elated to find groundbreaking research already taking place in a federally legal environment,” stated Tracy
Ryan, CEO of CannaKids. “It is with great pride that we announce this alignment between CannaKids, CURE and Technion as we
work towards ushering in a new line of cannabinoid therapies to the pharmaceutical marketplace for those suffering from both adult
and pediatric cancers. We are in a brave new world of plant-based cannabinoid medicines, and it is an honor to be working
alongside such brilliant minds.”
“This research partnership with Technion, which has one of the leading cannabis laboratories in the world, is a crucial step in
our goal to bring new cancer-fighting cannabinoid molecules to market,” said Rob Davidson, CEO of CURE. “In this work the Technion
team aims to clarify the antitumor effects of phytocannabinoids and terpenes on various cancer-driving mutations and pathways, as
well as further elucidating the mechanism of the cannabinoid-mediated antitumor effects. This will allow not only the
identification of new drug candidates but also will create the ability to optimize cannabis treatment options for patients.
Together these options further efforts toward the creation of personalized medicine.”
Technion’s lab group recently discovered two new pathways that have been activated by cannabis extracts in cancer cells.
Technion is looking forward to this partnership and working with CURE to continue uncovering the vast therapeutic potential of
the cannabinoids found in various cannabis species. Accumulating evidence indicates that cannabinoids have antitumor effects, as
several studies have demonstrated the use of cannabinoids in being able to regress different cancer types. This research
collaboration with CURE will help the company with their goal of determining which cannabis strains might be used to tackle
different cancer cells and what cannabinoid compounds within the plant are responsible for the ability to kill these cells.
Earlier this month, CURE announced its formal entrance into the pharmaceutical cannabis sector, which in the U.S. is
estimated to reach over $23 billion by 2020, according to ArcView Market Research. CURE’s goal is to bring new cannabinoid
molecules to the market through the FDA regulatory process, while utilizing the company’s proprietary delivery technologies to
increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based
options.
About CURE Pharmaceutical
Headquartered in Oxnard, California, CURE Pharmaceutical (OTC:CURE) is a fully integrated specialty pharmaceutical/bioscience
company that leverages disruptive proprietary drug delivery technologies for a broad range of molecules serving the
biopharmaceutical, veterinarian, medical foods and pharmaceutical cannabis markets. CURE develops its patented and proprietary
delivery system (CureFilm™), the most advanced oral thin film on the market today, from its industry leading full service cGMP
manufacturing facility. The Company’s mission is to deliver proven drugs in a fast and efficient manner and to improve quality of
life.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About CURE Pharmaceuticals and Pharmaceutical Cannabis
CURE Pharmaceutical is taking a leadership role in optimizing plant base cannabinoids, by vertically integrating drug discovery,
proprietary extraction technology, genetic-specific cannabinoids research, and drug development. CURE’s strategy is to bring
new cannabinoid molecules to the market through the FDA regulatory approval process while utilizing its proprietary delivery
technologies to increase efficacy as well as widening the overall therapeutic index.
About CannaKids
CannaKids is a California Cooperative Corporation headquartered in Sherman Oaks, California that has developed a full line of
cannabinoid therapies to help aid patients with various conditions. Providing medical clinicians and wellness coaches who
specialize in both Western medicine and anecdotal cannabinoid dosing, CannaKids prides themselves on having experienced caregivers
on hand to help ensure a patient has a positive experience. CannaKids’ CEO Tracy Ryan started her company after seeing success
when using cannabinoid therapy on her own daughter after she was diagnosed with a rare brain tumor at the age of 8 ½ months
old. After establishing CannaKids in mid-2014, Mrs. Ryan partnered with scientists and pediatric physicians to formulate her
own product line that was later released into the California Market in March of 2015. CannaKids has now worked with over 500
California based medical cannabis patients, and is excited to move forward with clinical research alongside CURE Pharmaceutical and
Technion-Israel Institute of Technology.
For more information on CannaKids please visit www.CannaKids.org.
About Technion-Israel Institute of Technology
The Technion-Israel Institute of Technology, long a key driver of Israeli innovation, and a hub for
the Start-Up Nation, has recently expanded to New York and China. It has earned a reputation as one of the world’s leading science
and technology universities. Its three Nobel Prize winners exemplify academic excellence. Technion people, ideas and inventions
make immeasurable contributions to the world, in areas including life-saving medicine, sustainable energy, computer science, water
conservation and nanotechnology.
Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than
statements of fact, including those statements with respect to the Company's business development, are forward-looking
statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We
undertake no obligation to publicly update or revise any forward-looking statements.
Public Relations Contact Andrew Hard Chief Executive Officer CMW Media andrew.hard@cmwmedia.com P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 284-9474 Lucia Domville, Grayling lucia.domville@grayling.com P. +1646 284-9416
